publication venue for
- Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?. 17:175-182. 2021
- Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease. 16:597-611. 2020
- Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. 15:395-404. 2019
- Rivaroxaban for prevention and treatment of venous thromboembolism. 15:63-77. 2019
- Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. 14:443-453. 2018
- Clinical implications of reversal agents for direct oral anticoagulants. 13:153-159. 2017
- Management considerations in the care of elderly heart failure patients in long-term care facilities. 10:563-577. 2014
- Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. 10:43-52. 2014
- Translating genomic analyses into improved management of coronary artery disease. 6:507-521. 2010
- Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease. 6:289-299. 2010
- Current and future uses of candesartan in the treatment of heart failure. 2:391-402. 2006